Table 3

Associations of breast cancer with IGF-I, IGF-II, and IGFBP-3 in all women

VariableNumberUnadjustedNumberAdjustedaAdjustedb
Case/controlOR95% CICase/controlOR95% CIOR95% CI
IGF-I (ng/ml)
Continuous
  ln (IGF-I)299/3002.47 (P < 0.001)1.45–4.22283/2912.23 (P = 0.007)1.25–3.991.46 (P = 0.279)0.73–2.92
Categorical (by tertile)
  ≤107.577/981.0072/961.001.00
  107.5–149.689/1011.180.75–1.8586/981.330.82–2.141.160.71–1.92
  ≥149.6133/1012.011.26–3.19125/971.951.18–3.231.490.85–2.59
Trend testP = 0.003P = 0.009P = 0.199
IGF-II (ng/ml)
Continuous
  ln (IGF-II)299/3002.51 (P = 0.050)1.00–6.31283/2911.76 (P = 0.280)0.63–4.88
Categorical (by tertile)
  ≤711.695/991.0092/941.00
  711.6–945.191/1001.060.66–1.7086/981.000.59–1.69
  ≥945.1113/1011.540.79–2.97105/991.220.58–2.57
Trend testP = 0.214P = 0.613
IGFBP-3 (ng/ml)
Continuous
  ln (IGFBP-3)299/3005.27 (P < 0.001)2.34–11.88283/2914.31 (P < 0.001)1.80–10.313.15 (P = 0.029)1.12–8.82
Categorical (by tertile)
  ≤369865/991.0062/961.001.00
  3698–439592/991.460.95–2.2388/961.280.81–2.041.160.71–1.88
  ≥4395142/1023.011.81–4.99133/993.001.70–5.312.501.37–4.58
Trend testP < 0.001P < 0.001P = 0.004
  • a Adjusted for BMI, age at menarche, age at first live birth, total energy intake, WHR, history of fibroadenoma, and family history of breast cancer.

  • b Adjusted for BMI, age at menarche, age at first live birth, total energy intake, WHR, history of fibroadenoma, family history of breast cancer, and either IGFBP-3 or IGF-I.